System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Observational Study Ppublish

PubMed: 40660539 DOI: 10.1097/MD.0000000000043250

Exploration of the correlation between metabolic dysfunction-associated steatotic liver disease and the FAM19A5 factor: A multivariate linear regression analysis.

Medicine (Baltimore) 104(28):e43250

Authors: Xiaoyan Huang, Miaohui Wu, Zexiang Wu, Kangyun Lu, Yancheng Lin, Kuoting Ho, Yi Zhang

Affiliations

  • Department of Endocrinology and Diabetes Center, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, China.
  • Department of Pharmacy, Jinjiang Municipal Hospital (Shanghai Sixth People's Hospital Fujian), Quanzhou, China.
  • Center for Precision Medicine, Yi-He Hospital, Quanzhou, China. HI. Q Biomedical Laboratory, Takyun Industrial Park, Quanzhou, China.
  • Center for Precision Medicine, Yi-He Hospital, Quanzhou, China.
  • HI. Q Biomedical Laboratory, Takyun Industrial Park, Quanzhou, China.
  • R&D Incubation Center, Collaboration Unit of Quanzhou Medical College-Hi. Q Biomedical Laboratory, Quanzhou, China.
  • Center for Precision Medicine, Yi-He Hospital, Quanzhou, China. HI. Q Biomedical Laboratory, Takyun Industrial Park, Quanzhou, China. R&D Incubation Center, Collaboration Unit of Quanzhou Medical College-Hi. Q Biomedical Laboratory, Quanzhou, China. College of Ocean Food and Biological Engineering, Jimei University, Xiamen, China.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by liver fat accumulation. Family with sequence similarity 19 member A5 (FAM19A5), a cytokine involved in metabolic regulation, may serve as a potential biomarker for MASLD diagnosis and treatment. A cross-sectional study was conducted on 37 participants from Quanzhou First Hospital between January and April 2024, including 18 MASLD patients and 19 healthy controls. Demographic data, anthropometric measurements, and clinical parameters were collected, and plasma FAM19A5 levels were quantified using Enzyme-Linked Immunosorbent Assay. After univariable analysis to screen variables associated with FAM19A5 levels, significant variables were included and potential confounders were adjusted for, followed by constructing multivariable linear regression models via stepwise variable selection. All statistical analyses were carried out using SPSS 26.0. Significant negative correlations were found between FAM19A5 levels and MASLD, body mass index, and total cholesterol. The expression of FAM19A5 was notably lower in MASLD patients, suggesting its potential role in the disease's pathophysiology. FAM19A5 could be a novel diagnostic biomarker for MASLD, with lower expression levels associated with the disease. Further research involving a broader patient population is needed to establish causality and explore its clinical implications.

MeSH

Liver Diseases, Regression Analysis, Metabolic Diseases, Liver, Biomarkers